Ask about this productRelated genes to: ACRV1 antibody
- Gene:
- ACRV1 NIH gene
- Name:
- acrosomal vesicle protein 1
- Previous symbol:
- -
- Synonyms:
- SPACA2, SP-10, D11S4365
- Chromosome:
- 11q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-06-07
- Date modifiied:
- 2014-11-19
Related products to: ACRV1 antibody
Related articles to: ACRV1 antibody
- <b>Introduction:</b> Pancreatic cancer is still an unresolved, significant diagnostic and clinical problem. An ideal tumor marker with a high sensitivity, organ specificity, and prognostic value that correlates with tumor stages and eliminates the imperfection of preoperative serum carbohydrate antigen 19-9 (CA 19-9) concentration is still being sought.<b>Aim:</b> This study aimed to conduct a comparative analysis expression of genes <i>KRAS, DPM1, ACRV1</i>, and <i>MBD3L2</i> in the saliva of patients with pancreatic cancer (PC) and a control group (CG).<b>Material and methods:</b> The study was performed on a group of 55 patients. Group 1 consisted of 44 patients with PC, group 2 (CG) consisted of 11 individuals who were recruited among patients operated on for non-inflammatory cholelithiasis. Group 1 was divided into 2 subgroups group 1a, 19 patients with resectable pancreatic tumors, and group 1b, 25 patients with unresectable pancreatic tumors. The saliva samples were taken from patients twice, before surgery and 10 days after surgery, and the expression of genes <i>KRAS, DPM1, ACRV1</i>, and <i>MBD3L2</i> in the saliva was evaluated. Gene expression at the transcriptional level was analyzed by assessing the number of mRNA copies using the reverse transcriptase reaction and polymerase chain reaction (RT-PCR).<b>Results:</b> The revealed expression of genetic cancer biomarkers (CB) (<i>KRAS, DPM1, ACRV1, MBD3L2</i>) in saliva was statistically significantly higher in the PC group in comparison to CG. There was a statistically significant decrease in the <i>KRAS</i> gene expression and a statistically significant increase in the <i>MBD3L2</i> expression in patients in subgroup 1a, 10 days after resection procedures. The revealed serum concentration of CA 19-9 was significantly higher in subgroup 1b in comparison to subgroup 1a. Although higher gene expression of <i>KRAS, DPM1</i>, and <i>MBD3L2 </i>was observed in subgroup 1b, no statistical significance was obtained. A statistically significant correlation between <i>DPM1</i> expression and serum CA 19-9 level in the PC group was observed. There were statistically significant differences in <i>KRAS </i>and <i>DPM1</i> expression depending on the tumor stage in the TNM/UICC classification regarding to T and N category. A significant difference in <i>MBD3L2</i> expression was observed in N category. A statistically significant increase in the expression of <i>KRAS, DPM1</i>, and <i>MBD3L2 </i>was observed in the case of neoplastic infiltration of blood vessels, and a significant increase in the expression of <i>KRAS</i> and <i>MBD3L2 <i/>in the case of neoplastic infiltration of nerve fibers.<b>Conclusions:</b> Presented findings suggest the usefulness of the salivary transcriptome profiles in distinguishing patients with PC from healthy controls but its usefulness in the differential diagnosis between resectable and unresectable PC is limited. However, more studies on a large population are needed to support our result. - Source: PubMed
Ciosek JakubDranka-Bojarowska DariaLewiński AdamLampe Paweł - Ovarian cancer (OC) remains a leading cause of gynecological cancer-related mortality, largely due to metabolic reprogramming and aggressive progression. Zinc finger protein 280A (ZNF280A), a poorly characterized transcriptional regulator, has recently been implicated in tumorigenesis, but its mechanistic role in OC remains undefined. Here, we identify ZNF280A as an oncogenic driver that promotes OC progression through transcriptional regulation of acrosomal vesicle protein 1 (ACRV1) and activation of the PI3K/AKT signaling pathway. ZNF280A expression was markedly elevated in OC tissues and cell lines and correlated with advanced clinicopathologic features and poor patient survival. Functional assays revealed that ZNF280A knockdown inhibited OC cell proliferation, migration, and tumorigenesis while inducing apoptosis both in vitro and in vivo. Mechanistically, ZNF280A enhanced ACRV1 transcription by interacting with the transcription factor CUX2, thereby facilitating its recruitment to the ACRV1 promoter. Elevated ZNF280A or ACRV1 expression activated PI3K/AKT signaling and increased glycolytic enzyme expression (PKM2 and LDHA), glucose uptake, lactate production, ATP generation, and extracellular acidification rate, whereas pharmacological inhibition of AKT or glycolysis abrogated these effects. Collectively, our findings establish ZNF280A as a key regulator of metabolic reprogramming in OC through the CUX2-ACRV1-PI3K/AKT axis, highlighting this pathway as a potential therapeutic target in ovarian cancer. - Source: PubMed
Publication date: 2025/12/01
Zhu DaweiChen PuyuYu LiangbinGao ShuaiLiu YiPan SilinLi Li - To explore the role of nuclear receptor-binding SET-domain protein 1 (NSD1) in the pathogenesis of nonobstructive azoospermia (NOA) by regulating the expressions of relevant genes. - Source: PubMed
Zhuang XuanCai Zhen-XinYang Yu-FengLi Zhi-Ming - Colorectal cancer (CRC) is the third most common malignancy worldwide and a leading cause of cancer-related mortality. Stromal signatures in CRC are correlated with poor prognosis and resistance to chemotherapy, affecting tumor progression and relapse. Although single-cell analyses have identified subpopulations of cancer-associated fibroblasts (CAFs), effective molecular targeted therapies against CAFs are lacking. - Source: PubMed
Publication date: 2025/07/31
Kato ShinyaMiyoshi NorikatsuFujino ShikiHorie MasafumiYachida ShinichiTakeda MitsunobuSekido YukiHata TsuyoshiHamabe AtsushiOgino TakayukiUemura MamoruYamamoto HirofumiYasui MasayoshiOhue MasayukiDoki YuichiroEguchi Hidetoshi - SYT13 is one of the atypical members of the synaptotagmin (SYT) family whose function has attracted considerable attention in recent years. Although SYT13 has been studied in several types of human cancers, such as lung cancer, its role in esophageal squamous cell carcinoma (ESCC) is still unclear. It was demonstrated that SYT13 is significantly upregulated in ESCC tissues compared with normal ones and correlated with higher degree of malignancy. Knockdown of SYT13 could inhibit ESCC cell proliferation and migration, while promoting cell apoptosis. Meanwhile, ESCC cells with relatively lower SYT13 expression grew slower and finally formed smaller xenografts. Furthermore, acrosomal vesicular protein 1 was identified as a potential downstream target of SYT13, which regulates cell phenotypes of ESCC cells in cooperation with SYT13. All the and results in this study identified that SYT13 silencing could be an effective strategy to inhibit the development of ESCC, which could be considered as a promising therapeutic target in the treatment of ESCC. - Source: PubMed
Publication date: 2024/07/24
Shao LonglongLi Bin